Imagine a smart security system for farms that not only blocks intruders but also tells you exactly who is a guest and who is a thief. This project creates high-tech vaccines and tests for four major animal diseases that cause miscarriages in pigs and sheep. It uses a special 'DIVA' technique so farmers can tell if an animal is actually sick or just vaccinated.
Livestock reproductive diseases cause massive economic losses and threaten food security. Current tools often fail to distinguish between a vaccinated animal and one that is naturally infected, complicating disease eradication.
A suite of rationally attenuated and subunit vaccines for PRRSV, Q fever, OEA, and B. suis, alongside DIVA-compatible ELISA and point-of-care diagnostic tests.
If you are a vaccine manufacturer dealing with low efficacy in traditional livestock shots — this project developed rationally attenuated and viral vectored vaccines that provide broader protection against PRRSV and Brucella suis.
If you are a diagnostic company dealing with slow lab turnaround times — this project developed point-of-care (PoC) tests that allow for immediate on-farm detection of OEA and Q fever.
If you are a large-scale farm dealing with economic losses from reproductive failure — this project developed DIVA-compatible tools to accurately monitor herd health and vaccine success.
Based on available project data, specific pricing or production costs are not provided.
The project includes 3 industrial partners and focuses on exploiting protein expression systems and refining vaccines for commercialisation, suggesting a path toward industrial scale.
Based on available project data, the new vaccines and diagnostics will be further developed by industrial partners to be made accessible to users, though specific licensing terms are not listed.
The project period runs from 2022-09-01 to 2027-08-31, indicating that final results and commercial refinements are expected by late 2027.
The project specifically develops point-of-care (PoC) tests, which are designed for rapid use on-site rather than requiring transport to a central laboratory.
The consortium is well-balanced for technology transfer, consisting of 18 partners across 8 countries. With a 17% industry ratio (3 companies) and a strong backbone of 7 universities and 7 research institutes, the project bridges the gap between fundamental structural biology and commercial veterinary application.
Contact AGENZIA NAZIONALE PER LE NUOVE TECNOLOGIE, L'ENERGIA E LO SVILUPPO ECONOMICO SOSTENIBILE in Italy.
Contact us to identify licensing opportunities for the DIVA-compatible diagnostic suite.
